Data Integrity

FDA Details Steps to Ensure Smooth Transition of IRBs

Institutional review boards that assume oversight of a clinical trial from another IRB should give drugmakers an opportunity to address any concerns the receiving IRB has with the study before it is terminated or suspended, an FDA final guidance says. Read More

Group Hopes to Turn Around Failed Lung Cancer Drugs

A UK coalition of drugmakers and a cancer research group are launching an analysis of failed Phase III lung cancer drug trials that will search for treatments that, despite failing overall, are effective for certain subpopulations. Read More